-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, tumor immunotherapy, especially immune checkpoint blockade (ICB) therapy represented by anti-PD-1/PD-L1 or CTLA-4, has achieved significant efficacy in a variety of cancers and has become a hot spot
On September 12, 2022, Professor Guo Anyuan of the School of Life Sciences of Huazhong University of Science and Technology published a book entitled "ICBatlas: A comprehensive resource for depicting immune" in Cancer Immunology Research, a prestigious journal of the American Association for Cancer Research (AACR).
Yang Mei, Miao Yaru and Xie Guiyan, doctoral students of the School of Life Sciences of Huazhong University of Science and Technology, are the co-first authors of the paper, Huazhong University of Science and Technology is the first of the paper, Professor Guo Anyuan of the School of Life Sciences of Huazhong University of Science and Technology and Professor Feng Jian of the Affiliated Hospital of Nantong University are the co-corresponding authors
Thesis Link: https://pubmed.
On September 8, 2022, a paper by Professor Guo Anyuan's research group entitled "Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy" was published
Thesis link:
Professor Guo Anyuan's team has long focused on tumor research, developed a series of tumor-related bioinformatics method platforms (ImmuCellAI, GSCA, GSCALite, FFLtool, etc.
